Company intelligence / Profile preview

LeadBio Tech

Ownership: Private
Development stage: Preclinical

Overview

LeadBio Tech develops bioartificial blood vessel medical devices aimed at advancing healthcare. The company was founded in 2019 and specializes in creating next-generation vascular grafts for potential use in surgery and regenerative medicine. There are no published clinical results or regulatory approvals yet[1].

Therapeutic areas: Cardiovascular
Modalities: Bioartificial blood vessels/medical devices
Industry: Implantable Medical Devices

Drug pipeline

3 assets

chloroquine

Pre-clinical

Indications: COVID-19

2 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships disclosed.

Beyond the preview

Go deeper on LeadBio Tech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LeadBio Tech.

Explore the full profile